<DOC>
	<DOCNO>NCT02773576</DOCNO>
	<brief_summary>A one year , open-label , study evaluate safety tolerability risperidone implant maintenance treatment patient schizophrenia</brief_summary>
	<brief_title>Safety Tolerability Risperidone Implants</brief_title>
	<detailed_description>The trial evaluate 48-week safety tolerability risperidone implant maintenance therapy subject schizophrenia . This measure incidence psychotic symptom exacerbation/impending relapse , PANSS , CGI-I , CGI-S , adverse event , vital sign , clinical laboratory , physical exam ECG finding , Abnormal Involuntary Movement Scale ( AIMS ) , Barnes Akathisia Rating Scale ( BARS ) , Simpson-Angus Scale ( SAS ) Investigator assessment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Subject provide write informed consent . 2 . Male female subject 18 70 year age , inclusive , time informed consent . 3 . Subjects current diagnosis schizophrenia define DSM5 criterion history illness least 2 year prior screen ( per subject , family , healthcare provider , and/or previous medical record ) . 4 . Subject assessed Investigator symptomatically stable regard psychiatric condition screen baseline . 5 . Subject must stable current antipsychotic medication least 30 day prior screen . 6 . Subject identify caregiver personal contact subject significant contact least per week . 7 . Subjects show previous response antipsychotic treatment ( clozapine ) past year , accord Investigator 's opinion . 8 . Subjects currently treat one two antipsychotic clozapine , , Investigator 's judgment , require chronic treatment antipsychotic medication would benefit treatment Risperidone Implants . 9 . Subjects meet follow criterion : 1 . Outpatient status 2 . PANSS Total Score ≤ 80 , PANSS score baseline increase ≥ 20 % change screening , subject participate study . 3 . PANSS score ≤ 4 follow item : Conceptual disorganization Suspiciousness Hallucinatory behavior Unusual thought content Hostility 4 . CGIS ≤ 4 ( moderately ill ) 5 . Lack clinically significant suicidal ideation behavior Investigator 's judgment 10 . Subjects able understand nature trial follow protocol requirement , ability read understand write word , reliably rat assessment scale . 11 . Subjects complete adequate washout ( 5 halflives unless otherwise specify ) prohibit concomitant medication , include mood stabilizer strong inducer inhibitor CYP2D6 activity , prior receive oral risperidone implant Risperidone . 12 . Subject complete washout 42 day fluoxetine contain compound . 13 . Female participant ( childbearing potential sexually active ) male participant ( sexually active partner childbearing potential ) agree use medically acceptable effective birth control method throughout study . 14 . Subject body mass index ( BMI ) ≥18.5 ≤38.0 kg/m2 . 15 . Subject assessed Investigator symptomatically stable regard preexist medical condition evidence medical history , nonclinically significant finding physical examination , vital sign , clinical laboratory evaluation ( hematology , serum chemistry , urinalysis ) 12lead electrocardiogram ( ECG ) . Subjects may continue current prescribed medication regimen control preexist medical psychiatric condition ( schizophrenia ) include use prescribe PRN medication . 1 . Known hypersensitivity allergy lidocaine local anesthetic agent amide type ( local anesthetic use implant explant procedure ) . 2 . Known sensitivity polyurethane . 3 . Reports reveals presence clinically significant skin disorder ( , limit , skin cancer , psoriasis , eczema , atopic dermatitis ) , and/or evidence recent sunburn , scar tissue , tattoo , open sore , body pierce brand intend implantation site would interfere implantation procedure interfere implant site assessment determine Investigator . 4 . History abnormal scar formation family history keloid formation . 5 . Subjects current DSM5 diagnosis schizophrenia , include schizoaffective disorder , major depressive disorder , bipolar disorder , delirium , dementia , amnestic cognitive disorder . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid , antisocial personality disorder exclude . 6 . Subjects experience acute depressive symptom within past 30 day , accord Investigator 's opinion , require treatment antidepressant . 7 . Subjects consider Investigator imminent risk suicide injury self , subject within past 6 month prior Screening attempt suicide , within past 3 month prior Screening active suicide ideation ( positive answer item 4 5 CSSRS ) . 8 . Subjects schizophrenia consider resistant/refractory antipsychotic treatment history . 9 . Subjects history failure clozapine treatment response clozapine treatment . 10 . Subjects document history failure respond adequate dose risperidone paliperidone treatment include long act injectable formulation . 11 . Subjects significant risk violent behavior significant risk commit suicide base history Investigator 's judgment . 12 . Subjects currently meet DSM5 criterion substance use disorder ( moderate severe ) ; include alcohol benzodiazepine , exclude caffeine , nicotine , marijuana . 13 . Females breastfeed breast feeding course study , and/or positive serum pregnancy test result prior receive trial medication . 14 . Subjects uncontrolled hypothyroidism hyperthyroidism ( unless condition stabilize medication least past 90 day ) . 15 . Subjects clinically significant history evidence medical condition would expose undue risk significant AE interfere assessment safety efficacy course trial . 16 . Subjects epilepsy history seizure , except single childhood febrile seizure , post traumatic , alcohol withdrawal , etc . A subject history seizure activity case discuss medical monitor prior subject 's study enrollment . 17 . Subjects positive drug screen screen drug abuse without prescription , exclude marijuana , discuss medical monitor . 18 . The following laboratory test , vital sign , ECG result exclusionary : 1 . Platelets ≤ 75,000/mm3 2 . Hemoglobin ≤ 9 g/dL 3 . Neutrophils , absolute ≤ 1000/mm3 4 . Aspartate aminotransferase &gt; 3x upper limit normal 5 . Alanine aminotransferase &gt; 3x upper limit normal 6 . Creatinine ≥ 2 mg/dL 7 . Diastolic blood pressure &gt; 105 mmHg 8 . QTc &gt; 470 msec female QTc &gt; 450 msec male use QTcF ( Fridericia ) correction 19 . Subject HIV positive . 20 . Active hepatitis . Subjects viral load , acute inflammation clinical necessity therapy allow , discretion Investigator . 21 . Subjects history allergic hypersensitivity antipsychotic agent . 22 . Subjects history significant intolerance refractory antipsychotic agent . 23 . Subjects history neuroleptic malignant syndrome . 24 . Subjects clinically significant tardive dyskinesia screen [ one AIMS item ( 17 ) score &gt; 2 ] . 25 . Subjects likely require prohibit concomitant therapy trial ( see Section 8.6.1 ) . 26 . Subjects require current use agent strong inhibitor ( e.g . quinidine ) inducer ( e.g . carbamazepine , phenytoin , rifampin , phenobarbital ) cytochrome P450 2D6 . 27 . Subjects receive investigational agent clinical trial within 30 day prior screen ; investigational drug elimination halflife great 15 day , time period extend 60 day . 28 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness , ongoing legal issue could affect ability continue participate trial . 29 . Subjects hospitalize , include hospitalization psychosocial reason , 30 day total last 60 day prior entry Screening Phase . 30 . Electroconvulsive therapy within 180 day prior entry Screening Phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>